Physician profile
John E Marsh
NPI 1699064659
$1,698.81
in general payments reported to CMS, 2019-2025
13 companies · $621 in 2025
The $621 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $311 · 2022: $149 · 2023: $363 · 2024: $255 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $770.26 | 2021-2025 | Eterna, Proclaim, Axium |
| Boston Scientific Corporation | $216.14 | 2021-2025 | General - Therapies |
| Medtronic, INC. | $170.73 | 2021-2025 | Kyphon Express II Kyphopak Tray, Inceptiv, Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $168.54 | 2021-2025 | Belbuca, Xtampza |
| Valinor Pharma, LLC | $103.26 | 2023-2025 | Movantik |
| Idorsia Pharmaceuticals US INC | $69.49 | 2023 | Quviviq |
| Nalu Medical, INC. | $40.86 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $36.30 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.06 | 2022-2025 | Relistor |
| Si-Bone, INC. | $32.40 | 2025 | |
| Emd Serono, INC. | $27.75 | 2021 | |
| Spinal Simplicity, LLC | $15.38 | 2024 | Ha Minuteman G3-R |
| Pfizer INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.